RealFeedApp Modera presents Phase 3 trial results for melanoma vaccine
CEO Stéphane Bancel announced that the custom mRNA therapy intismeran successfully improved patient outcomes in Phase 3 trials, with results set to be presented at the European Society for Medical Oncology annual meeting.
- Field
- cancer research
- What they did
- Moderna CEO Stéphane Bancel announced the results of a Phase 3 clinical trial showing that a customized mRNA therapy called intismeran improved outcomes for melanoma patients.
- Why it matters
- This success validates a decade of research and offers hope for better cancer treatments.
#mrna#melanoma#clinical trial#moderna#intismeran
